Eli Lilly’s new biotech R&D deals highlight a strategy of expanding discovery bets across multiple targets

Eli Lilly is drawing attention for a pair of fresh research and licensing agreements with biotechs that focus on “multi-target” discovery work, a setup that can broaden the number of chances a drug candidate has to succeed even before a single clinical program is fully defined. In a market report published June 25, the deals involving Abbisko Therapeutics and BioArctic were described as the kind of arrangements that can change how investors underwrite Lilly’s near- to mid-term pipeline momentum.

The report ties the Abbisko agreement to milestone payments that could total up to about 1.90 billion U.S. dollars, suggesting a structured set of payments linked to progress across the research collaboration. For readers, milestone payments generally refer to pre-agreed sums that are triggered when a program reaches defined steps, such as discovery milestones, development milestones, or regulatory and commercialization milestones.

While the details in the market report emphasize the “multi-target” nature of the discovery work, the core idea is that the collaborations are not limited to a single biological hypothesis at the outset. Multi-target discovery typically means teams pursue multiple related targets, aiming to increase the probability of identifying compounds with the right combination of efficacy and safety profiles. If successful, these efforts can feed licensed candidates back into the sponsor’s broader development pipeline.

The other announced relationship described in the report involves BioArctic, which also entered a multi-target R&D and licensing arrangement with Lilly. Taken together, the two deals were presented as an incremental but important expansion of Lilly’s external innovation network, with multiple projects structured to create optionality rather than a single, linear path from discovery to development.

From a sector perspective, this kind of collaboration-heavy approach has become a common feature of big pharmaceutical R&D as companies balance expensive late-stage trials with the need to replenish pipeline assets. External collaborations can also help sponsors access specialized discovery platforms and target expertise that may be harder to build internally at speed.

Still, the market report does not, in the text provided here, specify which therapeutic areas are covered, which specific targets are included in the multi-target programs, or what portions of the milestone schedules depend on Lilly versus its biotech partners. It also does not state whether the agreements will yield any named clinical-stage candidates in the near term, leaving investors to infer timing and impact rather than receive a detailed near-dated pipeline update.